Browse the evidence

Long-term intensive lifestyle intervention (weight loss via caloric restriction and increased physical activity) significantly improves and preserves performance-based physical function (gait speed and lower extremity function) in overweight/obese middle-aged and older adults with type 2 diabetes, despite anticipated loss of lean mass.

For older adults with type 2 diabetes, aiming for modest weight loss (around 10%) and increasing physical activity to about 175 minutes per week can help maintain mobility and walking speed over the long term. This benefit persists even if you lose some muscle mass, so don't let the fear of 'losing muscle' stop you from trying lifestyle changes.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater weight loss (up to 20.9%) compared to selective GLP-1 receptor agonists (e.g., semaglutide) by activating both GIP and GLP-1 signaling pathways in the brain and peripheral tissues.

If you have obesity and lifestyle changes alone haven't worked, a dual GIP/GLP-1 agonist like tirzepatide (Mounjaro/Mounjaro) is currently one of the most effective medical treatments available. It is taken as a once-weekly injection and can lead to nearly 21% body weight loss in clinical trials, which is significantly higher than older GLP-1 drugs. Be prepared for potential mild stomach issues during the first few months as your dose increases, but these often subside. This treatment is intended for adults with obesity or overweight with at least one weight-related condition.

Semaglutide 2.4 mg weekly produces significant weight loss (approx. 14.9%) in overweight and obese adults without diabetes, significantly outperforming placebo and older GLP-1 agonists like liraglutide.

Semaglutide 2.4 mg (Wegovy) is a once-weekly injection approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Clinical trials show it can lead to an average 14.9% body weight loss over 68 weeks when combined with diet and exercise. This is significantly more effective than older GLP-1 drugs like liraglutide. Common side effects include nausea and diarrhea, which are usually mild and decrease over time.

Diets high in ultra-processed foods cause excess ad libitum energy intake and weight gain compared to minimally processed diets, even when macronutrients and presented calories are matched.

Prioritize whole, minimally processed foods. Even if you match the calories and macros, ultra-processed foods make you eat more because of their physical structure and hyper-palatability. Focus on food quality and processing level, not just nutrient numbers.

Barbell velocity and Reps in Reserve (RIR) based RPE are practical, reliable, and strongly correlated with resistance training performance, making them superior tools for autoregulating load and volume.

Use a barbell speed tracker or estimate your Reps in Reserve (RIR) to adjust your weights. If you are using RIR, stop a set when you feel you could only do 1-2 more reps with good form. This ensures you are training close to failure without excessive fatigue.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, dose-dependent weight loss in patients with type 2 diabetes, making them superior to weight-gain-promoting medications like insulin and sulfonylureas for weight-centric management.

If you have Type 2 Diabetes and struggle with weight, ask your doctor about GLP-1 agonists (like semaglutide) or dual agonists (like tirzepatide). These drugs not only control blood sugar but also promote significant weight loss (up to 15-20% in trials) by slowing digestion and reducing appetite, unlike older drugs like insulin which often cause weight gain.

Once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention significantly reduces body weight in adults with obesity or overweight.

If you have obesity or overweight with related health issues, ask your doctor about once-weekly semaglutide injections (2.4 mg). It works by suppressing appetite and slowing digestion, leading to significant weight loss (around 15% in trials) when combined with diet and exercise. Be aware of potential stomach issues like nausea, which often improve over time.

Ultra-processed diets cause increased energy intake and weight gain compared to unprocessed diets, likely due to modifications in the food matrix affecting satiety and nutrient bioavailability.

Be aware that ultra-processed foods are engineered to bypass normal satiety signals, leading to passive overconsumption. This is not a personal failure but a property of the food. To manage weight, prioritize foods that naturally promote satiety (whole foods) and limit UPF.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and dual GLP-1/GIP agonists (tirzepatide 15 mg) produce significant, superior weight loss compared to placebo and older anti-obesity medications.

If you have obesity, newer GLP-1 or dual agonist medications (like semaglutide or tirzepatide) are significantly more effective for weight loss than older drugs or lifestyle changes alone. These require weekly or daily injections and work by mimicking hormones that control appetite and digestion. They are generally safe but require medical supervision, especially if you have a history of thyroid cancer or pancreatitis.

Cardiorespiratory fitness is a vital sign that strongly predicts reduced morbidity and mortality, and even small increases in fitness (1.0-1.5 METs) provide significant protective effects against chronic disease and premature death.

Focus on improving your cardiorespiratory fitness, as it is the strongest predictor of living longer and healthier. You don't need to be an elite athlete; even small improvements (equivalent to walking slightly faster or climbing a few flights of stairs) can significantly reduce your risk of heart disease, cancer, and premature death. Consider fitness a vital sign to track.

Treatment with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality in overweight or obese adults without diabetes compared to placebo.

If you are overweight or obese and do not have diabetes, treatment with GLP-1 or GIP/GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide) has been shown in large studies to significantly lower your risk of major heart events (like heart attack and stroke) and death from any cause compared to taking a placebo. This benefit exists independently of diabetes status.

Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves superior HbA1c reduction (up to 2.6%) and weight loss (up to 15.7%) compared to other GLP-1 RAs and insulin, making it a highly effective treatment for T2D and obesity.

Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones. It is highly effective for lowering blood sugar (up to 2.6% HbA1c reduction) and promoting significant weight loss (up to 15.7%). It is more effective than many other GLP-1 RAs and insulin, making it a top-tier option for managing T2D and obesity, despite being an injection.

GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, achieving 18-21% body weight reduction in clinical trials. They work by changing how your brain signals hunger and fullness, not just by making you feel full. This can be particularly helpful if you have struggled with dieting in the past. Combining the medication with behavioral therapy yields the best results.

GLP-1 receptor agonist therapies significantly reduce total cardiovascular events, major adverse cardiovascular events (MACE), and all-cause mortality in nondiabetic individuals with overweight or obesity compared to placebo.

For nondiabetic adults who are overweight or obese, using GLP-1 receptor agonist therapies (such as semaglutide, tirzepatide, or liraglutide) significantly lowers the risk of heart attacks, strokes, and death from any cause compared to placebo. This benefit exists independently of diabetes status, suggesting these drugs should be considered for cardiovascular risk reduction in this population, not just for weight loss.

New generation incretin analogues (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) produce sustained mean weight reductions of 15-20% in adults with BMI ≥27 kg/m², significantly outperforming older agents and lifestyle interventions alone.

If you have a BMI over 27, talk to your doctor about semaglutide or tirzepatide. These are weekly injections (or oral pills for semaglutide) that help you lose 15-20% of your body weight, which is much more than older drugs. You must also follow a lifestyle plan with diet and exercise.

Tirzepatide (5-15 mg weekly) achieves mean weight loss of 15-21% in adults with BMI ≥27 kg/m², demonstrating superior efficacy compared to placebo and potentially other GLP-1 agonists.

Tirzepatide is a weekly injection available in doses up to 15mg. It can help you lose over 20% of your body weight if you have a BMI over 27. Side effects like nausea are common but often manageable. It is approved for obesity management in the US and UK.

Obesity medications are indicated for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with complications) and must be used in conjunction with lifestyle interventions to optimize effectiveness and health outcomes.

If you have obesity or are overweight with a related health issue, medications are a valid medical option, but they work best when paired with diet and exercise changes. You must meet specific BMI criteria (usually 30+, or 27+ with health issues). Crucially, if you start a medication and don't lose at least 5% of your body weight after 12 weeks at the maximum dose, you should stop it, as it likely won't work for you. However, for those who respond, these drugs can significantly improve health markers and quality of life.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual agonists (Tirzepatide) provide superior weight loss and metabolic benefits compared to older agents like Orlistat or Phentermine, with Semaglutide and Tirzepatide showing the highest efficacy.

Newer injectable medications like Semaglutide and Tirzepatide are significantly more effective for weight loss than older oral drugs like Orlistat. Tirzepatide, in particular, has shown high efficacy in trials, with many users losing 15-20% of their body weight. These are weekly injections and are generally well-tolerated, though gastrointestinal side effects are common during dose escalation.

Bariatric surgery and pharmacotherapy (e.g., GLP-1 agonists) are indicated for many patients with obesity to achieve and maintain weight loss, especially when lifestyle interventions fail.

If lifestyle changes aren't enough, talk to your doctor about medication or surgery. These treatments target the biology of obesity and can significantly improve health conditions like diabetes and heart disease.

Chronic pharmacotherapy with GLP-1 receptor agonists (semaglutide 2.4 mg) and dual agonists (tirzepatide 10-15 mg) produces significantly greater and more sustained weight loss than behavioral interventions alone by neutralizing counter-regulatory physiological mechanisms.

If you have obesity, lifestyle changes alone often fail long-term because your body fights back by increasing hunger hormones. New medications like semaglutide (weekly injection) or tirzepatide (weekly injection) work by overriding this biological defense, allowing for significantly greater weight loss (often >15%) than diet and exercise alone. These are intended for chronic use to maintain results.

Tirzepatide (10-15 mg) produces greater mean weight loss than semaglutide (2.4 mg) in head-to-head comparisons, achieving reductions of up to 20.9%.

Tirzepatide is a weekly injection that targets two hormones (GIP and GLP-1) to maximize weight loss, often resulting in ~20% body weight reduction. It requires slow dose escalation to manage stomach side effects.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are effective pharmacotherapies for obesity, producing significant weight loss and cardiovascular benefits.

GLP-1 medications like semaglutide are highly effective for weight loss and cardiovascular health. They are a standard treatment for obesity, not a cosmetic fix. Discuss them with your doctor.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) and multi-agonists (retatrutide, CagriSema, survodutide) produce clinically significant weight loss (typically >10-20%) in adults with obesity, with efficacy increasing with dose and number of receptor targets.

GLP-1 based medications (like semaglutide and tirzepatide) are highly effective for significant weight loss (15-20%+) in adults with obesity, often outperforming lifestyle changes alone. They work by targeting hormonal receptors to reduce appetite and slow digestion. While effective, they require medical supervision due to potential side effects like nausea, which usually subside with dose titration. They are indicated for those with a BMI over 27 with complications or over 30.

Unimolecular polypharmacology using dual (GLP-1R/GIPR or GLP-1R/GCGR) or triple (GLP-1R/GIPR/GCGR) agonists produces superior weight loss and glycemic control compared to single-agonist GLP-1 receptor agonists.

If you have obesity or type 2 diabetes, newer medications that target multiple hormones (GLP-1, GIP, and Glucagon receptors) like tirzepatide or retatrutide are significantly more effective for weight loss and blood sugar control than older single-target drugs like semaglutide. These are taken as once-weekly injections. While they can cause stomach issues, they are generally well-tolerated and offer superior results. Consult a doctor to see if you qualify for these treatments.